



#6/attach. 1646

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(MBHB00,814-A 400.034)

PATENT

In the Application of: McSwiggen, et al. )  
Serial No. 09/927,046 ) Examiner: TBA  
Filed: August 9, 2001 ) Art Unit: 1646  
For: METHOD AND REAGENT FOR THE )  
INHIBITION OF CALCIUM ACTIVATED )  
CHLORIDE CHANNEL-1 (CLCA-1) )

RECEIVED

JAN 21 2003

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In regard to the above identified application:

1. We are transmitting herewith the attached papers for the above identified new patent application:

- ☒ Supplemental Information Disclosure Statement;
- ☒ Supplemental PTO Form-1449 including (4 cited references);
- ☒ Copy of International Search Report; and
- ☒ Return Receipt Postcard.

2. With respect to additional fees, no additional fee is required.

3. **GENERAL AUTHORIZATION:** Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.


4. **CERTIFICATE OF MAILING UNDER 37 CFR § 1.8:** I hereby certify that I directed that this Transmittal Letter and the correspondence identified above be deposited with the United States Postal Service as "First Class Mail," addressed to the Commissioner for Patents, Washington, DC 20231, on the date indicated below.

Date: January 13, 2003

By:

Andrew W. Williams  
Reg. No. 48,644

McDonnell Boehnen Hulbert & Berghoff  
300 South Wacker Drive, Fl. 32  
Chicago, IL 60606  
Telephone: (312) 913-0001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(MBHB00,814-A 400.034)

PATENT

In the Application of:

McSwiggen, et al.

Serial No. 09/927,046

Filed: August 9, 2001

For: METHOD AND REAGENT FOR THE  
INHIBITION OF CALCIUM ACTIVATED  
CHLORIDE CHANNEL-1 (CLCA-1)

Commissioner for Patents  
Washington, D.C. 20231

Examiner: TBA

Art Unit: 1646

RECEIVED

JAN 21 2003

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to the duty of disclosure provided by 37 C.F.R. § 1.56 and §§ 1.97-98, the applicants wish to make all references listed in the PTO-1449 form enclosed herewith of record in the above-identified application. It is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Also, enclosed is a copy of the International Search Report in which the references listed on the enclosed 1449 were cited during the prosecution of a corresponding PCT application. Each item of information contained in the present Information Disclosure Statement was first cited in this


International Search Report for the corresponding PCT application not more than three months prior to the filing of this Information Disclosure Statement.

Portions of the references may be material to the examination of the pending claims, however no such admission is intended. 37 C.F.R. 1.97 (h). The references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. sections 102 or 103.

Respectfully submitted,

**McDonnell Boehnen Hulbert & Berghoff**

Date: January 13, 2003

By:   
Andrew W. Williams  
Registration No. 48,644

#6/Suppl.  
I.D.S.

<b>FORM PTO-1449</b> (Rev. 2-32)  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	<b>U.S. Department of Commerce Patent and Trademark Office</b>	<b>Atty. Docket No.</b>  00,814-A (400.034)	<b>Serial No.</b>  09/927,046
	<b>Applicant:</b>  James McSwiggen et al.		
	<b>Filing Date:</b>  8/09/2001	<b>Group:</b>  1646	

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
1.	WO 98/32846	7/30/1998	PCT				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

2.	Genbank Accession No. AF039400, "Homo sapiens calcium-dependent chloride channel-1 (hCLCA1) mRNA, complete cds," December 14, 1998.
3.	Ludwig et al., "Extending the cleavage rules for the hammerhead ribozyme: mutating adenosine 15.1 changes the cleavage site specificity from N16.2U16.1H17 to N16.2C16.1H17," Nucleic Acids Research 26(10):2279-2285 (1998).
4.	Vaish et al., "In vitro selection of a purine nucleotide-specific hammerhead-like ribozyme," Proc. Natl. Acad. Sci. USA 95:2158-2162 (1998).

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.